ArticleMolecular pharmaceutics2017
Alleviation of Multiple Asthmatic Pathologic Features with Orally Available and Subtype Selective GABA
Abstract read
In one paragraph
Article in Molecular pharmaceutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Lung-Targeted Delivery of Nebulized α‑Asaronol Attenuates Airway Inflammation and Hyperresponsiveness in Murine Asthma Models.ACS pharmacology & translational science · 2026Article
- Design, Synthesis, and Biological Evaluation of Novel Spiro Imidazobenzodiazepines to Identify Improved Inhaled Bronchodilators.Journal of medicinal chemistry · 2023Article
- Comparative pharmacodynamic and pharmacokinetic study of MIDD0301 and its (S) enantiomer.Drug development research · 2022Article
- Development of Inhaled GABAACS pharmacology & translational science · 2022Article
- GABAergic signaling by cells of the immune system: more the rule than the exception.Cellular and molecular life sciences : CMLS · 2021Review
- Neuroimmune Pathophysiology in Asthma.Frontiers in cell and developmental biology · 2021Review
- Identification and Quantification of MIDD0301 Metabolites.Current drug metabolism · 2021Article
- Nebulized MIDD0301 Reduces Airway Hyperresponsiveness in Moderate and Severe Murine Asthma Models.ACS pharmacology & translational science · 2020Article
- A Structure-Activity Relationship Comparison of Imidazodiazepines Binding at Kappa, Mu, and Delta Opioid Receptors and the GABAMolecules (Basel, Switzerland) · 2020Article
- Targeting Nitric Oxide Production in Microglia with Novel Imidazodiazepines for Nonsedative Pain Treatment.ACS chemical neuroscience · 2020Article
- MIDD0301 - A first-in-class anti-inflammatory asthma drug targets GABABasic & clinical pharmacology & toxicology · 2019Article
- A novel GABAAmerican journal of physiology. Lung cellular and molecular physiology · 2019Article
- A Novel Orally Available Asthma Drug Candidate That Reduces Smooth Muscle Constriction and Inflammation by Targeting GABAMolecular pharmaceutics · 2018Article
- Design and Synthesis of Novel Deuterated Ligands Functionally Selective for the γ-Aminobutyric Acid Type A Receptor (GABAJournal of medicinal chemistry · 2018Article
- Molecular Characterization of GABA-A Receptor Subunit Diversity within Major Peripheral Organs and Their Plasticity in Response to Early Life Psychosocial Stress.Frontiers in molecular neuroscience · 2018Article
- Synthesis of chiral GABAARKIVOC : free online journal of organic chemistryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 2 institutions in 1 country.
Gloria S ForkuoDepartment of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee , Milwaukee, Wisconsin 53201, United States.
Amanda N NiemanDepartment of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee , Milwaukee, Wisconsin 53201, United States.
Nina Y YuanDepartment of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee , Milwaukee, Wisconsin 53201, United States.
Revathi KodaliDepartment of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee , Milwaukee, Wisconsin 53201, United States.
Olivia B YuDepartment of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee , Milwaukee, Wisconsin 53201, United States.
Nicolas M ZahnDepartment of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee , Milwaukee, Wisconsin 53201, United States.
Rajwana JahanDepartment of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee , Milwaukee, Wisconsin 53201, United States.
Guanguan LiDepartment of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee , Milwaukee, Wisconsin 53201, United States.
Michael Rajesh StephenDepartment of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee , Milwaukee, Wisconsin 53201, United States.ORCID 0000-0003-0027-6560
Margaret L GuthrieDepartment of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee , Milwaukee, Wisconsin 53201, United States.
Michael M PoeDepartment of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee , Milwaukee, Wisconsin 53201, United States.
Benjamin D HartzlerDepartment of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee , Milwaukee, Wisconsin 53201, United States.
Ted W HarrisDepartment of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee , Milwaukee, Wisconsin 53201, United States.
Gene T YocumDepartment of Anesthesiology, Columbia University , New York, New York 10032, United States.
Charles W EmalaDepartment of Anesthesiology, Columbia University , New York, New York 10032, United States.
Douglas A SteeberDepartment of Biological Sciences, University of Wisconsin-Milwaukee , Milwaukee, Wisconsin 53201, United States.
Douglas C StaffordDepartment of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee , Milwaukee, Wisconsin 53201, United States.
James M CookDepartment of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee , Milwaukee, Wisconsin 53201, United States.ORCID 0000-0001-5512-3022
Leggy A ArnoldDepartment of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee , Milwaukee, Wisconsin 53201, United States.ORCID 0000-0003-1411-1572
University of Wisconsin–Milwaukee · USColumbia University · US
Funding
Neuromuscular blocker-induced asthma during anesthesiaR01GM065281 · NIGMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI EMALA, CHARLES W · 2003 to 2018
$5.4MDevelopment of new drugs for asthma by targeting GABA(A) receptors in the lungR01HL118561 · NHLBI · UNIVERSITY OF WISCONSIN MILWAUKEE · PI COOK, JAMES M · 2014 to 2017
$2.0MDesign of New Therapeutic Agents to Treat SchizophreniaR01MH096463 · NIMH · UNIVERSITY OF WISCONSIN MILWAUKEE · PI COOK, JAMES M · 2013 to 2017
$1.9MTargeting airway smooth muscle chloride fluxes for bronchorelaxationR01HL122340 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI EMALA, CHARLES W · 2015 to 2018
$1.6MSynthesis of Alpha2/Alpha3 GABA Agonists to Treat Neuropathic PainR01NS076517 · NINDS · UNIVERSITY OF WISCONSIN MILWAUKEE · PI COOK, JAMES M · 2012 to 2015
$1.3MSmall molecule inhibitors of the vitamin D receptor-coactivator interactionR03DA031090 · NIDA · UNIVERSITY OF WISCONSIN MILWAUKEE · PI ARNOLD, ALEXANDER · 2010 to 2011
$73kNHLBI NIH HHS R01 HL118561NHLBI NIH HHS R01 HL122340NIDA NIH HHS R03 DA031090NIGMS NIH HHS R01 GM065281NIMH NIH HHS R01 MH096463NINDS NIH HHS R01 NS076517
Abstract
We describe pharmacokinetic and pharmacodynamic properties of two novel oral drug candidates for asthma. Phenolic α
Indexed as
AnimalsAsthmaBronchoalveolar Lavage FluidDisease Models, AnimalEosinophilsFlow CytometryHumansLungMaleMiceMice, Inbred BALB COvalbuminReceptors, GABARespiratory HypersensitivitySwineOvalbuminReceptors, GABAairway hyperresponsivenessairway inflammationasthmaGABAA receptorleukocytessplenocytesα4β3γ2α5β3γ2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.